AIM ImmunoTech (AIM) announced that data were published on Roswell Park Comprehensive Cancer Center’s Phase 1 study evaluating AIM ImmunoTech’s drug Ampligen as a component of a chemokine-modulating (CKM) regimen in early-stage triple-negative breast cancer, TNBC,. Results of the study were reported in The Journal for ImmunoTherapy of Cancer. “We are very excited with these promising results from our study of a new treatment combination for patients with this most highly aggressive form of breast cancer, triple-negative breast cancer,” said study principal investigator Shipra Gandhi, MD, Associate Professor of Oncology and staff physician in the Department of Medicine at Roswell Comprehensive Cancer Center. “Because this initial study was in a small number of patients, it will be important to validate these findings in a larger study.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AIM:
- Kellner Group urgers stockholders of AIM Immunotech to vote for nominees
- Aim Immunotech Reports Third Quarter Earnings
- AIM ImmunoTech files to sell 9.31M shares of common stock for holders
- Berkshire reveals stake in Domino’s, Alibaba reports mixed Q2: Morning Buzz
- Morning Movers: Spectrum Brands dips after fourth quarter earnings